27 October 2020
  • Share

Our client, Hummingbird Bioscience, has received regulatory authorisation to initiate clinical trials for their SARS-CoV-2-targeted antibody, HMBD-115.  Developed with partners in Singapore and the US, the commencement of trials for HMBD-115 is a significant milestone for the company, who have been working on an antibody therapy for COVID-19 since the emergence of the disease. Early read-out of the ongoing Phase I/II clinical trial of HMBD-115 is expected in December 2020, and a Phase III trial is scheduled for the end of 2020.

Neutralizing antibodies to SARS-CoV-2 are promising therapeutics for COVID-19, and offer an important treatment option in the absence of an effective vaccine, and for at-risk patients who may respond poorly to a vaccine. Pre-clinical studies have shown that HMBD-115 dramatically lowers circulating infectious virus and reduces inflammatory immune responses, which are a feature of severe disease.

Learn more about HMBD-115 at Hummingbird Bioscience's website.

About Hummingbird Bioscience

Hummingbird Bioscience, founded in 2015 in Singapore, is a clinical-stage biotech company that uses systems biology and data science to better understand disease mechanisms and how to treat these, through the development of rationally engineered bio-therapeutics.

Adam is a Partner and Patent Attorney at Mewburn Ellis. He works with biotech companies to build and manage their patent portfolios, drafting patent applications and co-ordinating prosecution worldwide. Adam has particular experience handling portfolios relating to therapeutics (particularly immunotherapies, including adoptive cellular therapies), antibody technology, diagnostics, and regenerative medicine.

Sign up to our newsletter: Forward - news, insights and features

Our People

Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.


Contact Us

We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany.  We’d love to hear from you, so please get in touch.